Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2009 Apr 26;64(3):629–633. doi: 10.1007/s00280-009-1004-y

Fig. 2. STI571 interferes with the ability of the MTT assay to measure cell viability.

Fig. 2

MDA-MB-435s melanoma cells and MDA-MB-468 breast cancer cells were plated in 96-well dishes in triplicate, the media was replaced the next day with media containing STI571 (a,c) or doxorubicin (b), and 72 hours later the cells were used either in MTT (a,b) or Cell Titer Glo (c) viability assays. Experiments shown are mean ± s.e.m. for three independent experiments. *p<0.05, **p<0.005, ***p<0.001 using Student t-tests. Some error bars are too small to be visualized.